GlassScriptPhysician profile
Morgan Aldridge
NPI 1346772779
$3,123.12
in general payments reported to CMS, 2019-2025
29 companies · $1,097 in 2025
The $1,097 reported for 2025 was more than what 91% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $240 · 2022: $553 · 2023: $694 · 2024: $539 · 2025: $1,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,329.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $466.27 | 2023-2025 | Myfembree, Gemtesa |
| Mayne Pharma Commercial LLC | $401.42 | 2021-2025 | |
| Organon LLC | $284.49 | 2022-2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $244.32 | 2021-2025 | |
| Abbvie INC. | $227.28 | 2021-2023 | Liletta, Lo Loestrin Fe |
| Astellas Pharma US INC | $175.07 | 2023-2025 | Veozah |
| Exeltis, USA INC. | $168.43 | 2021-2025 | Slynd |
| Myovant Sciences INC. | $164.38 | 2021-2022 | |
| Hologic Sales and Service, LLC | $145.51 | 2023-2025 | Acessa Provu System, Aptima, Thinprep 2000 Processor |
| Evofem Biosciences, INC. | $127.15 | 2021-2023 | Phexxi |
| Coopersurgical, INC. | $108.57 | 2022-2025 | Paragard T 380a, Summit Doppler |
| Dexcom, INC. | $86.88 | 2025 | Dexcom G6 Transmitter |
| Myriad Women'S Health, INC. | $59.43 | 2023 | Myrisk |
| Pfizer INC. | $59.07 | 2022-2025 | |
| Ethicon US, LLC | $50.73 | 2021-2023 | Stratafix, Harmonic |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $48.76 | 2024-2025 | Femring, Intrarosa, Femlyv |
| Baxter Healthcare | $33.44 | 2023 | |
| Mylan Pharmaceuticals INC. | $32.56 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $30.05 | 2024 | Ultomiris |
| Scynexis, INC. | $27.95 | 2022 | |
| Sage Therapeutics, LLC | $27.67 | 2024-2025 | Zurzuvae |
| Innovation Technologies INC | $26.39 | 2025 | Irrisept |
| Seqirus USA INC | $21.78 | 2025 | Flucelvax |
| Shield Therapeutics INC | $21.55 | 2022 | |
| Boston Scientific Corporation | $19.80 | 2022 | |
| Lilly USA, LLC | $18.53 | 2025 | Zepbound, Mounjaro |
| Currax Pharmaceuticals LLC | $16.09 | 2024 | Contrave |
| Coloplast Corp | $15.94 | 2025 | |
| Therapeuticsmd, INC. | $13.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Aldridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.